痴呆
疾病
唐氏综合症
医学
人口
基因检测
阿尔茨海默病
儿科
精神科
病理
内科学
环境卫生
作者
Juan Fortea,Shahid Zaman,Sigan L. Hartley,Michael S. Rafii,Elizabeth Head,María Carmona‐Iragui
标识
DOI:10.1016/s1474-4422(21)00245-3
摘要
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI